PREOPANC Trial: Survival in the Control Arm and Role of Radiation Need More Explanation

Affiliations

¹ Ankit Jain, MBBS, MD, DM, DNB, Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; Sivakumar Gananadha, MBBS, MS, Department of Surgery, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; Amy Shorthouse, BSc, BMed (Hons), Department of Radiation Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; and Desmond Yip, MBBS, Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia.

Comment

Ankit Jain et al. J Clin Oncol. 2022.

. 2022 Oct 1;40(28):3346-3347.

doi: 10.1200/JCO.22.00538. Epub 2022 Jun 23.

¹ Ankit Jain, MBBS, MD, DM, DNB, Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; Sivakumar Gananadha, MBBS, MS, Department of Surgery, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; Amy Shorthouse, BSc, BMed (Hons), Department of Radiation Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia; and Desmond Yip, MBBS, Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia, ANU Medical School, Australian National University, Canberra, ACT, Australia.

No abstract available

Comment in

Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al.
Versteijne E, van Dam JL, Besselink MG, Groot Koerkamp B, Homs MYV, Wilmink JW, van Eijck CH, van Tienhoven G. Versteijne E, et al. J Clin Oncol. 2022 Oct 1;40(28):3348-3351. doi: 10.1200/JCO.22.00875. Epub 2022 Jun 23. J Clin Oncol. 2022. PMID: 35737926 No abstract available.

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CHJ; Dutch Pancreatic Cancer Group. Versteijne E, et al. J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27. J Clin Oncol. 2022. PMID: 35084987 Clinical Trial.